<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635193</url>
  </required_header>
  <id_info>
    <org_study_id>206OC202</org_study_id>
    <secondary_id>2007-000509-31</secondary_id>
    <nct_id>NCT00635193</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)</brief_title>
  <official_title>A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study of liposomal doxorubicin with or without volociximab for the
      treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer
      relapsed after prior therapy with Plat/Taxane-based chemo. Volociximab is an anti-angiogenic
      integrin inhibitor being developed for the treatment of solid tumors. Preclinical data with a
      surrogate volociximab antibody administered as monotherapy indicate encouraging efficacy in
      terms of tumor reduction and anti-angiogenic effects in mouse ovarian cancer xenograft
      models. In clinical studies, volociximab has been evaluated in several solid tumor types,
      including pancreatic, renal, and melanoma, with many subjects who entered the studies with
      progressive disease remaining progression-free for several months. In all studies in solid
      tumors, volociximab has shown a favorable safety profile when administered at 10 mg/kg q2wks
      and more recently at 15 mg/kg qwk. A study of volociximab in combination with liposomal
      doxorubicin in subjects with ovarian cancer or primary peritoneal cancer who have relapsed
      after prior platin/taxane therapies is warranted to further evaluate the drug's efficacy and
      safety. The investigators have thus far activated stage 2 of this study at 11/25 sites.
      Worldwide, the study aims to enroll 150 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study of liposomal doxorubicin with or without volociximab for the
      treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer
      relapsed after prior therapy with Plat/Taxane-based chemo. Volociximab is an anti-angiogenic
      integrin inhibitor being developed for the treatment of solid tumors. Preclinical data with a
      surrogate volociximab antibody administered as monotherapy indicate encouraging efficacy in
      terms of tumor reduction and anti-angiogenic effects in mouse ovarian cancer xenograft
      models. In clinical studies, volociximab has been evaluated in several solid tumor types,
      including pancreatic, renal, and melanoma, with many subjects who entered the studies with
      progressive disease remaining progression-free for several months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of volociximab in combination with liposomal doxorubicin in advanced epithelial ovarian cancer or primary peritoneal cancer. To evaluate the safety and tolerability of volociximab in combination with liposomal doxorubicin.</measure>
    <time_frame>50-57 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Ovarian Cancer, Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>liposomal doxorubicin, 40 mg/m2 q4wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M200 (Volociximab)</intervention_name>
    <description>7.5 mg/kg, IV infusion every week until disease progression</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin</intervention_name>
    <description>40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M200 (Volociximab)</intervention_name>
    <description>15 mg/kg, IV infusions every week until disease progression</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M200 (Volociximab)</intervention_name>
    <description>15 mg/kg, IV infustions every other week until disease progression</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged &gt;= 18 years old at the time of informed consent.

          -  Advanced (Stage III or IV) histologically documented epithelial ovarian cancer or
             primary peritoneal cancer (excluding small, round-cell histologies).

          -  Recurrent or persistent disease.

          -  Received no more than 2 prior cancer treatment regimens, at least one of which must
             have included a platinum/taxane based therapy. If the same regimen is given more than
             once, it will count as one regimen. If components of a regimen are given more than
             once using the same schedule, it will count as one regimen.

          -  At least 1 target lesion to assess response by RECIST criteria. (Tumors within a
             previously irradiated field are designated as non-target)

          -  Other protocol-defined inclusion criteria apply.

        Exclusion Criteria:

          -  Subjects taking immunomodulatory agents including, but not limited to, interferons,
             interleukins, systemic steroids, cyclosporine, tacrolimus, calcineurin inhibitors,
             chronic low dose methotrexate, or azathioprine. (Use of inhaled or intranasal steroids
             or oral steroids 10 mg/day prednisone or its equivalent are permitted.)

          -  Subjects who require treatment with an anti coagulant with the exception of low dose
             AspirinÂ® (81 mg/day), warfarin (1 mg/day), or heparin for IV catheter patency

          -  Evidence of bleeding diathesis or coagulopathy. (Prior history of DVT will not exclude
             subjects from participating in this study.)

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 1.

          -  Non-healing wound, ulcer, or bone fracture.

          -  Evidence of autoimmune disease including, but not limited to, ulcerative colitis,
             Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and
             other disease in which immune function or immune competence is known to be impaired.

          -  Active infection requiring systemic antibiotics, antivirals, or antifungals including
             HIV/AIDS, hepatitis B, or hepatitis C infection.

          -  Other protocol-defined exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihail Obrocea, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75281</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75275</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75296</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75299</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75300</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75301</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75274</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75294</name>
      <address>
        <city>Jackson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75279</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75295</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75280</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75297</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75298</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75278</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75334</name>
      <address>
        <city>Toorak Gardens</city>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75335</name>
      <address>
        <city>Woodville South</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75337</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75336</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75338</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75415</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75333</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75344</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75339</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75341</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75342</name>
      <address>
        <city>Poznan</city>
        <zip>61-001</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75343</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75345</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75340</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75346</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75348</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75347</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75349</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75351</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75352</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75350</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75353</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75354</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75355</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75416</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <disposition_first_submitted>May 4, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 14, 2012</disposition_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian neoplasms</keyword>
  <keyword>Angiogenesis inhibitors</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Volociximab</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Antibody</keyword>
  <keyword>Monoclonals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

